|
| Characteristics | Case 1 | Case 2 |
|
| Age (years) | 65 | 50 |
| Sex | Male | Male |
| Ethnicity | Chinese | Chinese |
| HBV status before chemotherapy | HBeAg negative,
Anti-HBe positive, HBV DNA 6.65E5 IU/mL, ALT 43 IU/L | HBeAg negative,
Anti-HBe positive, HBV DNA 8.90E4 IU/mL*, ALT 37 IU/L |
| Prior hepatitis B treatment | No | No |
| Clinical evidence of advanced liver fibrosis | Absent | Absent |
| Fibrosis stage | Fibroscan 4.4 KPa (F0) | APRI 0.19 (F0-1) |
| Comorbidities | Hypothyroid, hypertension, latent tuberculosis infection | Gout, psoriasis |
| Medications used | Levothyroxine, valsartan, isoniazid, pyridoxine, metformin | Calcipotriol/betamethasone ointment, Chinese herbal tea |
| Diffuse, large B-cell lymphoma stage | Stage IIA | Stage III |
| Lymphoma treatment | R-CHOP x 6 | R-CHOP x 6 |
| Lamivudine start date | 8 days after first chemotherapy | 4 days after first chemotherapy |
| HBV DNA after 2 months of LAM treatment | 2.18E1 IU/mL | 3.96E3 IU/mL |
| Time of HBV reactivation diagnosis | 18 weeks after R-CHOP number 6 | 7 weeks after R-CHOP number 6 |
| Duration of LAM at HBV reactivation | 7 months | 7 months |
| Lamivudine resistance pattern | L80I, M204I | L80I, M80V, M204V/S |
| HBV status at reactivation | HBeAg negative, anti-HBe positive, HBV DNA 1.43E7 IU/mL, ALT 1019 IU/L | HBV DNA 1.02E8 IU/mL, ALT 902 IU/L |
| Time to death despite tenofovir treatment | 14 days | 3 days |
|
